NINR Asks Nurses for Meaning of Research
What does the future of nursing research mean to you? How can nurse scientist-led studies provide information you can use in your daily practice? What gaps do you see in evidence to support nursing care?
Manage Immune-Related Adverse Events in Patients on Durvalumab
Durvalumab immunotherapy became a new standard of care for patients with stage III unresectable non-small cell lung cancer whose disease did not progress following two cycles of platinum-based chemoradiotherapy after its approval in February 2018, and in March 2020, its indication was expanded for use as first-line treatment in patients with extensive-stage small cell lung cancer as well. Key to keeping patients on immunotherapy treatment and giving them the best chance at long-term survival is effective management of immune-related adverse events.
House of Representatives; Nurse Scientists; Women in Congress
Cori Bush, a nurse and Black Lives Matter activist, beat U.S. Representative William Lacy Clay (D-MO), a sitting 20-year incumbent, to win the Democratic nomination in St. Louis, MO. Bush will be the newest nurse to U.S. Congress, should she win her seat in November, which is highly likely. She’d join the ranks of U.S. Representatives Lauren Underwood (D-IL) and Eddie Bernice Johnson (D-TX) to bring a critical nursing perspective directly to the United States’ legislative branch.
President Trump Issues Executive Orders on Prescription Drug Pricing
In July 2020, U.S. President Donald Trump issued four executive orders to provide solutions to the ever-increasing price of prescription medications. One of the top domestic issues in healthcare is the price of prescription medication, particularly those deemed lifesaving, such as insulin for diabetics and drugs for patients with cancer.
How Can ONS Support Members in Today’s Practice Changes?
In response to public health concerns from the COVID-19 coronavirus pandemic, the U.S. government, healthcare institutions, and payors rapidly developed new policies and procedures to address the changing landscape.
FDA Grants Accelerated Approval to Belantamab Mafodotin-Blmf for Multiple Myeloma
On August 5, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to belantamab mafodotin-blmf (Blenrep) for adult patients with relapsed or refractory multiple myeloma who received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
- Read more about FDA Grants Accelerated Approval to Belantamab Mafodotin-Blmf for Multiple Myeloma
- Add new comment
Glioblastoma Diagnosis, Treatment, Side Effect Management, and Survivorship Recommendations
Glioblastoma or glioblastoma multiform (GBM) is a primary central nervous system tumor. Approximately 23,890 new brain tumors are diagnosed in the United States each year, with GBM accounting for 38%. GBM can present as a primary diagnosis or evolve from a lower grade brain tumor.
- Read more about Glioblastoma Diagnosis, Treatment, Side Effect Management, and Survivorship Recommendations
- Add new comment
A Single Blood Test Could One Day Identify 10 Types of Cancer
When combined with positron-emission and computed tomography, a multicancer blood test identified 10 different tumor types in a sample of women with no history of cancer, researchers reported in Science.
FDA Grants Accelerated Approval to Tafasitamab-Cxix for Diffuse Large B-Cell Lymphoma
On July 31, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tafasitamab-cxix (Monjuvi®), a CD19-directed cytolytic antibody, indicated in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplant.
- Read more about FDA Grants Accelerated Approval to Tafasitamab-Cxix for Diffuse Large B-Cell Lymphoma
- Add new comment
Not All Barriers to Care Are Created Equal
Every patient deserves equal access to health care. Yet 68% of patients have at least one social determinant of health that serves as a barrier to care.